Morgan Stanley
-
Europe’s high grade bond market provided some mixed indications of sentiment on Monday with the deals for Takeda and SEE seeing notable differences in demand, leaving syndicate bankers trying to work out what this means for what is expected to be a busy week of issuance. -
DirectBooks, which plans to bring a new issuance platform for bond markets, has not ruled out the possibility of a partnership with other providers.
-
OcuMension Therapeutics hit the market on Monday with its HK$1.55bn ($200m) IPO, the latest in a stream of healthcare sector listings on the city’s stock exchange.
-
Cambodian casino company NagaCorp sold a new dollar bond – and only the second from the country – this week, raising $350m.
-
Worldline, the French payments company, received a warm reception from bond investors on Tuesday, setting aside any concerns that the scandal at German competitor Wirecard would sully sentiment towards the sector.
-
Shenzhen Hepalink Pharmaceutical Group launched its Hong Kong IPO this week, targeting proceeds of HK$4.53bn ($585m).
-
Ghana Cocoa Board (Cocobod), the central organisation for Ghana’s cocoa industry, is in the process of raising its annual syndicated loan, but bankers say the borrower is running into difficulty as lenders’ risk appetite weakens.
-
Worldline, the French payments company, received a warm reception from bond investors on Tuesday, putting aside any concerns that the scandal at German competitor Wirecard would sully sentiment towards the sector.
-
CNP Assurances and Helvetia Europe have added to issuance momentum in the insurance sector, giving investors the chance to put money into subordinated capital. The tier two bonds showed that ‘the market is back in shape’, said one deal arranger.
-
Agora is looking to raise up to $315m from its Nasdaq IPO, having begun bookbuilding for the deal.
-
Drug developer SK Biopharmaceuticals priced its IPO high last Friday, netting W959.3bn ($792m), according to a source close to the deal.
-
Kangji Medical Holdings has bagged HK$3.59bn ($464.2m) after pricing its Hong Kong listing at the top of the marketed range.
